Lobe Sciences, Ltd. is a biopharmaceutical company focused on using lipid technology to develop treatments for orphan and rare diseases. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The Company commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.

• Revenue in CAD (TTM)0.00
• Net income in CAD-4.54m
• Incorporated2010
• Employees--

• Location
  Lobe Sciences Ltd1771 Robson Street #1614VANCOUVER V6G 3B7CanadaCAN
• Phone+1 (604) 834-9499
• Fax+1 (604) 628-1249
• Websitehttps://www.lobesciences.com/